In vitro and in vivo Immunoadjuvant Effects of the Enzymatically Modified Fucoidan

Objectives. No sulfated polysaccharides (fucoidans) has been declared as the pharmaceutical substances, adjuvants, etc., which is associated with the problems of obtaining the structurally characterized and homogeneous samples or their oligomeric fractions that retain high biological activity. The highly purified fucoidan with regular reproducible structural characteristics (F1) was obtained by enzymatic hydrolysis of native fucoidan (F2). Aim. The comparative study of fucoidans from the brown alga Fucus evanescens (F1 and F2) effects on the effector functions of innate and adaptive immunity cells loaded with ovalbumin (OVA) in vitro and in vivo. Material and methods. Fucoidan F1 — the enzymatically modified product of native fucoidan; F2 — the native fucoidan. The fucoidans effects on the expression level of the main immunophenotypic markers of innate and adaptive immunity (neutrophils, monocytes, natural killers, lymphocytes) cells in vitro were studied by methods of flow cytometry. The fucoidans effects on the production of serum OVA-specific antibodies (IgG, IgG1, IgG2а) and cytokines (IFNγ, IL-2, IL-10, IL-12) were detected in BALB/c mice immunized with OVA. Results. The tested fucoidans activate the effector functions of innate and adaptive immunity cells loaded with OVA in vitro and act as adjuvants, stimulating both Th1 (IgG2а, INFγ, IL-2) and Th2 (IgG1, IL-10) immune response to OVA in vivo. Conclusions. The immunoadjuvant effect of the enzymatically modified fucoidan (F1) on effector functions of innate and adaptive immunity cells are comparable to those of the native fucoidan (F2). The findings determine the possibility of F1 use as an adjuvant for a wide range of prophylactic and therapeutic vaccines.

1. Alekseyenko T.V., Zhanayeva S.Y., Venediktova A.A., Zvyagintseva T.N., Kuznetsova T.A., Besednova N.N., Korolenko T.A. Antitumor and antimetastatic activity of fucoidan, a sulfated polysaccharide isolated from the Okhotsk Sea Fucus evanescens brown alga. Bull Exp Biol Med. 2007; 143 (6): 730–732. doi: 10.1007/s10517-007-0226-4.

2. Anastyuk S.D., Shevchenko N.M., Ermakova S.P., Vishchuk O.S., Nazarenko E.L., Dmitrenok P.S., Zvyagintseva T.N. Anticancer activity in vitro of a fucoidan from the brown alga Fucus evanescens and its low-molecular fragments, structurally characterized by tandem mass-spectrometry. Carbohydr Polym. 2012; 87 (1): 186–194. https://doi.org/10.1016/j.carbpol.2011.07.036.

3. Menshova R.V., Shevchenko N.M., Imbs T.I., Zvyagintseva T.N., Malyarenko O.S., Zaporoshets T.S., Besednova N.N., Ermakova S.P. Fucoidans from brown alga Fucus evanescens: structure and biological activity. Front Marine Sci. 2016; 3: 1–9. doi: 10.1177/1934578X1801300837.

4. Zaporozhets T.S., Kryzhanovsky S.P., Persianova E.V., Kuznetsova T.A., Smolina T.P., Gazha A.K., Shevchenko N.M., Ermakova S.P., Zvyagintseva T.N., Besednova N.N. The corrective effect of fucoidan, a sulfated polysaccharide extracted from brown algae Fucus evanescens, in the formation of a specific immune response against seasonal influenza viruses in the elderly. Antibiotiki i Khimioter = Antibiotics and Chemotherapy. 2020; 65 (3–4): 23–28. https://doi.org/10.37489/0235-2990-2020-65-3-4-23-28.

5. Silchenko A.S., Rasin A.B., Kusaykin M.I., Malyarenko O.S., Shevchenko N.M., Zueva A.O., Kalinovsky A.I., Zvyagintseva T.N., Ermakova S.P. Modification of native fucoidan from Fucus evanescens by recombinant fucoidanase from marine bacteria Formosa algae. Carbohydr Polym. 2018; 193: 189–195. doi: 10.1016/j.carbpol.2018.03.094.

6. Anastyuk S.D., Shevchenko N.M., Dmitrenok P.S., Zvyagintseva T.N. Structural simi-larities of fucoidans from brown algae Silvetia babingtonii and Fucus evanescens, determined by tandem MALDI-TOF mass spectrometry. Carbohydr Res. 2012; 358: 78–81. doi: 10.1016/j.carres.2012.06.015.

7. Ikewaki N., Iwasaki M., Kurosawa G., Rao K.-S., Lakey-Beitia J., Preethy S., Abraham S.J.K. β glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B VACCIEN) in specific immunocompromised populations. Hum Vaccin Immunother. 2021; 17 (8): 2808–2813. https://doi.org/10.3892/or.2021.8225.

8. Kim S.-Y., Joo H.-G. Evaluation of adjuvant effects of fucoidan for improving vaccine efficacy. J Vet Sci. 2015; 16 (2): 145–150. doi: 10.4142/jvs.2015.16.2.145.

9. Kuznetsova T.A., Persiyanova E.V., Ermakova S.P., Khotimchenko M.Yu., Besednova N.N. The sulfated polysaccharides of brown algae and products of their enzymatic transformation as potential vaccine adjuvants. Nat Prod Com. 2018; 13 (8): 1083–1095. doi: 10.1177/1934578X1801300837.

10. Pifferi C., Fuentes R., Fernández-Tejada A. Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action. Nat Rev Chem. 2021; 5: 197–216. doi: 10.1038/s41570-020-00244-3.

11. Zhang W., Oda T., Yu Q., Jin J.O. Fucoidan from Macrocystis pyrifera has powerful immune-modulatory effects compared to three other fucoidans. Mar Drugs. 2015; 13: 1084–1104. doi: 10.3390/md13031084.

12. Seder R.A., Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature. 2000; 406:793–798. doi: 10.1038/s41570-020-00244-3.

13. Coffman R.L, Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010; 33 (4): 492–503. doi: 10.1016/j.immuni.2010.10.002.

14. McKee A.S., Munks M.W., Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007; 27: 687–690. doi: 10.1016/j.immuni.2007.11.003.

15. Mathers A.R., Cuff C.F. Role of Interleukin-4 (IL-4) and IL-10 in serum immunoglobulin G antibody responses following mucosal or systemic reovirus. Infect J Virol. 2004; 78: 3352–3360. doi: 10.1128/jvi.78.7.3352-3360.2004.

16. Gherardi R.K., Eidi H., Crepeaux G., Authier F.J., Cadusseau J. Biopersistence and brain translocation of aluminum adjuvants of vaccines. Front Neurol. 2015; 6: 4. doi: 10.3389/fneur.2015.00004.